Efficacy News and Research

RSS

Experimental gene therapy holds promise against metastatic prostate cancer

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.

12 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

Human Papillomavirus (HPV) is a leading cause of sexually transmitted diseases, with more than 70% of sexually active people getting the virus at least once in their lifetimes. Persistent infection with some HPV strains can lead to cervical cancer, the second most common cancer in women, as well as to head-and-neck and other types of cancer and anogenital warts in both men and women.

10 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine.

8 May 2015

UT Southwestern testing Vivistim System device in stroke patients

UT Southwestern Medical Center will be one of three national sites to pioneer U.S. testing for an implant device that stimulates the vagus nerve in stroke patients to see whether it can help restore lost arm function.

7 May 2015

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD).

7 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.

7 May 2015

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

Transition Therapeutics Inc. today announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company.

6 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

Lymphatic pump treatment (LPT) shows promise in managing pneumonia when combined with antibiotic treatment, according to a new study published in The Journal of the American Osteopathic Association.

5 May 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that activity and tolerance data for its second lead product Col-Treg were presented through a poster presentation at the 2015 ARVO Annual Meeting, May 3-7, 2015, in Denver, Colorado, US.

5 May 2015

Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy.

5 May 2015

Moderate exercise on a regular basis may improve cancer treatments

Kansas State University kinesiology research offers encouraging information for cancer patients: A brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.

5 May 2015

Scientists produce low-allergen, low anti-nutritional inhibitor soybean

In the United States, nearly 15 million people and 1 in 13 children suffer from food allergy. In Arizona alone, every classroom contains at least two children with a food allergy. Soybeans are one of the eight foods regulated by the Food Allergen Labeling and Consumer Protection Act, or FALPA. Soybean is a major ingredient in many infant formulas, processed foods and livestock feed used for agriculture. Soybeans contain several allergenic and anti-nutritional proteins that affect soybean use as food and animal feed.

5 May 2015

Efficacy News and Research

Experimental gene therapy holds promise against metastatic prostate cancer

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Scientists identify key factors in parents' decision-making about HPV vaccination of daughters

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Noninvasive nuclear medicine test can help determine effectiveness of aromatase inhibitor treatment

UT Southwestern testing Vivistim System device in stroke patients

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

Cardiff scientists develop novel anti-cancer stem cell compound

Scientists uncover new pharmaceutical strategy for treating melanoma

Transition Therapeutics acquires worldwide rights from Lilly to develop, commercialize TT701

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

Novel Ga-68-PSMA-ligand PET/CT effective for early detection of prostate cancer recurrence

Moderate exercise on a regular basis may improve cancer treatments

Scientists produce low-allergen, low anti-nutritional inhibitor soybean

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News